CN Patent

CN104876937B — 8‑氟‑2‑{4‑[(甲氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂*并[5,4,3‑cd]吲哚‑6‑酮的马来酸盐、其药物组合物及其用途

Assigned to Pfizer Inc · Expires 2017-07-28 · 9y expired

What this patent protects

本发明涉及8‑氟‑2‑{4‑[(甲氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂 并[5,4,3‑cd]吲哚‑6‑酮(式I)的马来酸盐、包含其的药物组合物及其用途。此类多晶型形式可以是药物组合物的成分，并且可用于治疗由聚(ADP‑核糖)聚合酶活性所介导的哺乳动物疾病病状，包括诸如癌症的疾病病状。

USPTO Abstract

本发明涉及8‑氟‑2‑{4‑[(甲氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂 并[5,4,3‑cd]吲哚‑6‑酮(式I)的马来酸盐、包含其的药物组合物及其用途。此类多晶型形式可以是药物组合物的成分，并且可用于治疗由聚(ADP‑核糖)聚合酶活性所介导的哺乳动物疾病病状，包括诸如癌症的疾病病状。

Drugs covered by this patent

Patent Metadata

Patent number
CN104876937B
Jurisdiction
CN
Classification
—
Expires
2017-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.